APC CEO Mark Barrett unveiled how APC is redefining how medicines are discovered, developed, and manufactured through its transformative digital strategy.
Public source
Publisher name
Public post
CEO Mark Barrett unveils how APC, an Industry leader in CMC Digitization, is redefining how medicines are discovered, developed, and manufactured. 'Through our transform…
Company
APC
- Industry
- Pharmaceutical Manufacturing
- Location
- Dublin, IE
- Company size
- 501–1,000 employees
About APC
APC helps biopharma companies slash drug development times by delivering breakthrough science at lightning fast process development speed. We thrive on radical collaboration, challenging ourselves and our clients to deliver for patients faster. *Breakthrough Science* We are process development experts – chemical and bioprocess engineers, organic and process chemists, statisticians, analysts, and project managers – who live to create better processes, build newer technology, and solve CMC problems that others shy away from. Our breakthroughs power pipelines and take CMC off the critical path. We work across modalities, from synthetics to cell and gene therapies, using world class process research, engineering and modelling to deliver the breakthroughs our clients once thought impossible. *Lightning Fast Development* Our singular objective is to be the best process development organization in the world, because to go fast you need focus. APC’s projects and partnerships deliver more CMC outcomes per unit time than anyone else and our technology platforms are changing the paradigm for speed in process development. We leave manufacturing to others; instead, we push our clients to broaden their CMO network, take control of their manufacturing strategy, and eliminate rework and failures from clinical and commercial supply. APC processes deliver right-first-time performance across the product lifecycle meaning our clients never slow down on the journey to their patients. *Radical Collaboration* We ask before we tell – and we strive for every client conversation to be more transparent and patient-focused than the last. We know that our clients are knowledge powerhouses and we constantly ask great questions designed to unlock that key insight that will propel a medicine from molecule to market faster. Our clients are on a mission to save lives. We help them.
See moreLatest activity
Latest activity from APC
7 signals
Presence & Recognition
APC is hosting an afternoon session on September 30th focused on nanoparticle therapeutics, rAAV production, advanced therapies, analytical innovation, PAT, and hybrid modelling.
Presence & Recognition
APC is hosting a focused morning on September 30th exploring practical approaches across flow chemistry, API morphology, crystallization, microscale drying, PAT and powder flow modelling.
Presence & Recognition
APC is participating in the Medicine Accelerator (TMA) event in Cambridge, MA, featuring small molecule development in the morning and large molecules in the afternoon.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Almac Group
Almac Group announced that Arran Chemical Company will transition to operate under the Almac Sciences name from 1st October 2026.
Strategy & Corporate Development
Milla Pharmaceuticals, an A.forall company
Milla Pharmaceuticals, an A.forall company announced US expansion, Licensing-In, Innovation, Commercialisation, and other initiatives.
Strategy & Corporate Development
AST
AST CEO and President Joe Hoff discussed how the company's purpose guides the team to make decisions and deliver innovative solutions for the pharmaceutical and biotechnology industries.
Strategy & Corporate Development
PolyPeptide Group
PolyPeptide Group is launching a new product line for the global market.
Strategy & Corporate Development
Cohance Lifesciences